Premium
The use of erythropoiesis‐stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib
Author(s) -
Crisà Elena,
Cilloni Daniela,
Elli Elena M.,
Martinelli Vincenzo,
Palumbo Giuseppe A.,
Pugliese Novella,
Beggiato Eloise,
Frairia Chiara,
Cerrano Marco,
Lanzarone Giuseppe,
Marchetti Monia,
Mezzabotta Mauro,
Boccadoro Mario,
Ferrero Dario
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15450
Subject(s) - myelofibrosis , ruxolitinib , medicine , erythropoiesis , international prognostic scoring system , anemia , erythropoietin , ineffective erythropoiesis , gastroenterology , myelodysplastic syndromes , bone marrow
Summary Erythropoiesis‐stimulating agents ( ESA s) were combined with ruxolitinib in 59 anaemic myelofibrosis patients (93% with Dynamic International Prognostic Scoring System [ DIPSS ] intermediate‐2/high risk; 52·5% transfusion‐dependent). Anaemia response ( AR ) rate was 54% and 76% of patients responded at 5 years. A further 15% displayed minor improvement in anaemia and 78% of patients reduced spleen size. Endogenous erythropoietin levels <125 u/l correlated with a higher AR rate (63% vs. 20%, P = 0·008). No thrombotic events or other toxicities occurred. Overall survival was 62% at 4 years, influenced by DIPSS and transfusion dependency. ESA s seem effective in improving anaemia in ruxruxolitinib‐treated myelofibrosis patients.